You are here

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma

 

Online download statistics by month:

Online download statistics by month: November 2022 to October 2025

AbstractFullPdf
Nov 2022606013
Dec 2022535539226
Jan 202343443451
Feb 202314314343
Mar 2023949544
Apr 2023737341
May 2023727336
Jun 2023606021
Jul 2023424225
Aug 2023666632
Sep 2023646425
Oct 2023828346
Nov 2023858533
Dec 2023727235
Jan 2024737463
Feb 2024939333
Mar 2024787876
Apr 2024717141
May 2024505033
Jun 2024646445
Jul 2024737435
Aug 2024323160
Sep 202418818838
Oct 2024525226
Nov 2024485124
Dec 2024343520
Jan 2025626232
Feb 2025959522
Mar 2025565728
Apr 2025848436
May 2025495034
Jun 2025373718
Oct 2025000
Total312131351335